Focused on metabolic liver disease, the company develops therapies targeting nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction–associated steatohepatitis (MASH). Its lead product, resmetirom, a thyroid hormone receptor‑beta agonist, received FDA approval in 2024,...
1 member of Congress has disclosed 1 trade in Madrigal Pharmaceuticals, Inc. (MDGL), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |